BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Sought-After Extravagance Ocean side Objections for a Lovely Escape - 2The Response to Independence from the rat race: Methodologies for Creating Financial momentum
- 32024 Moving Styles for Kitchen Redesigns
- 4Pick Your Number one sort of blossom
- 5More than 800 flights canceled as FAA cuts traffic at 40 major airports. Here's what to know.
- Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines
- Step by step instructions to Explore Assessment Ramifications of Disc Rates
- Who plays Moana in the live-action remake? What to know about Catherine Lagaʻaia.
- Baby takes 1st steps after receiving groundbreaking gene-edited therapy
- Well known Tea Brands for Each Tea Sweetheart
- Steinmeier honours Italian 'guest workers' who rebuilt German economy
- 6 Home Cleaning Administrations to Keep Your Home Unblemished
- A 'rampaging lion' nebula roars to life in a stunning deep-space photo
- Manual for Savvy Home Lighting Framework: Lights up Your Space
